The Role Of IP Law In Shaping Personalized Medicine Accessibility - A Case Study Of India
Author: LawSphereX
Category: General Law
Published:
Updated:
THE ROLE OF IP LAW IN SHAPING PERSONALIZED
MEDICINE ACCESSIBILITY: A CASE STUDY OF INDIA
Benazir Guru S, Sastra Deemed to be University
ABSTRACT
Personalized medicine has tremendous potential to enhance healthcare outcomes by customizing treatments based on individual genetic profiles, particularly in fields such as oncology, genetic diseases, and infectious diseases. Nonetheless, the challenges of accessibility and affordability for these therapies remain significant, especially in low and middle-income nations like India. In India, intellectual property (IP) laws, particularly patents, play a vital role in influencing the accessibility of innovative treatments. Although India possesses a strong generic pharmaceutical sector and has utilized the flexibilities permitted under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, patent law and IP practices continue to create both opportunities and obstacles for personalized medicine.
This paper investigates how India's IP framework affects the availability and affordability of personalized medicine. It looks into India's implementation of compulsory licensing, assesses the function of the Indian patent system in maintaining access to essential medications, and analyses the consequences of IP law for the future of personalized therapies.
Introduction
India plays a crucial role in the global healthcare sector, recognized for its major contributions to the generic drug industry and its ability to utilize flexibilities within the international patent framework to enhance access to vital medications. As personalized medicine, which customizes treatments according to an individual's genetic profile, becomes more prominent, there are growing concerns regarding the implications of patent protection on the availability of these innovative therapies. With the high expenses linked to personalized drugs and diagnostics, India confronts a significant challenge in reconciling intellectual property protections with the need for healthcare that is both affordable and accessible.
India’s patent legislation, influenced by the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, adopts a balanced approach: it not only provides tools to safeguard innovation and promote the creation of new therapies but also incorporates flexibilities that permit the manufacturing and distribution of costeffective generic alternatives to patented medicines. This paper will examine how India’s intellectual property framework affects the accessibility of personalized medicine and how its developing patent system could be adjusted to fulfil public health needs. Literature Review "Patents and the Price of Innovation: Causal Evidence from the Human Genome" (Heidi L. Williams) This paper investigates the effect of patenting in genomics, including personalized medicine, on the pricing of genetic tests and therapeutic products.
It analyzes the cause-and-effect relationship between the rise in intellectual property protections for genomic innovations and the resulting prices of genetic tests. The research reveals that the growing number of genomic patents raises the costs of both genetic diagnostics and treatments, which in turn affects accessibility within the healthcare system. Intellectual Property and Access to Medicine: A New Global Framework? ” (Bhaven N. Sampat) This paper examines the global debate on the influence of intellectual property on access to medications and healthcare, particularly in developing nations. It analyses how patents can hinder the advancement and availability of cost-effective treatments.
Although it does not concentrate exclusively on personalized medicine, it offers valuable perspectives on the overall issue of how intellectual property systems impact access to healthcare innovations. "Economic and Ethical Implications of Patents for Personalized Medicine” (Michele M. Borkin) This paper analyzes the economical and ethical consequences of patenting innovations associated with personalized medicine. It addresses how patents, especially in the field of genomics, can restrict the affordability of new therapies by establishing monopolies that drive up costs for patients. The article also investigates the ethical challenge of reconciling intellectual property protections with the necessity for broad access to potentially life-saving personalized treatments.
Research Problem Personalized medicine frequently entails significant upfront expenses, due to genome sequencing, targeted therapies and the requirement for advanced diagnostics. While there is a significant body of literature regarding the expenses linked to pharmaceuticals and the affordability of traditional medicines in relation to IP. However, there is a lack of exploration into how the IP regime particularly patents, impacts the affordability and availability of personalized medicines. This research strives to investigate how the existing IP system can be modified to make the advantages of personalized medicines available to a broader segment of the population, especially in low and middle-income communities. Research Methodology This paper follows a doctrinal research methodology.
This approach focusses on analyzing the existing IP laws and relevant secondary sources to explore the impact of availability and affordability of personalized medicine. Research Method Secondary sources of data are used for this research paper. Research Questions a) How do India's current patent laws affect the accessibility and affordability of personalized medicine for patients in low and middle-income communities? b) How could India modify its patent laws to better support equitable access to personalized medicine, especially in resource-constrained settings?
Research Objective The goal of this research is to analyse the existing obstacles and prospects offered by India’s intellectual property system concerning personalized medicine. More specifically, it seeks to suggest approaches that India might implement to enhance access to personalized therapies, particularly in light of escalating expenses and the intricacies surrounding patents on advanced treatments, all while preserving the motivating factors for innovation that patents are designed to encourage. The Indian IP Framework and Personalized Medicine The Role of IP in Personalized Medicine Intellectual property (IP) significantly influences the advancement of personalized medicine by fostering innovation, safeguarding discoveries, and determining access to novel treatments. A crucial element of IP within personalized medicine is the patent protection for genetic and biomarker findings.
Researchers and organizations frequently patent genetic sequences and biomarkers associated with particular diseases, which are essential for developing tailored therapies. However, the rise of patents for similar or overlapping genetic sequences can pose challenges to the accessibility of treatments, as licensing agreements and patent barriers may restrict access to tests or therapies linked to these biomarkers. Simultaneously, there exists a conflict between patent exclusivity and the need to keep these innovations accessible. While patents encourage research and development, they can lead to concerns regarding the affordability and availability of personalized therapies, especially for rare diseases or among low-income populations. This balance between promoting innovation through patent protection and ensuring public access is a significant concern.
Custom therapies also pose difficulties regarding patent eligibility. In contrast to conventional medications that target broad patient demographics, personalized treatments are frequently customized for individuals based on their genetic profiles, which complicates traditional patenting methods. This raises concerns about how intellectual property frameworks can evolve to consider the distinct, individualized aspects of personalized medicine, particularly when treatments might be tailored for a single patient or a limited group. Compulsory licensing is another key concept regarding intellectual property and personalized medicine. This legal approach permits governments to bypass patent rights during public health crises, and it may gain importance as personalized treatments for diseases such as cancer, HIV, and genetic disorders become more prevalent.
The possibility of applying compulsory licensing in the realm of personalized medicine prompts inquiries about how intellectual property regulations can be designed to promote both innovation and accessibility, ensuring that essential treatments are obtainable despite patent restrictions. Personalized medicine is deeply rooted in genetic testing, biomarkers, targeted therapies, and companion diagnostics, all of which are generally safeguarded by patents. The patent law in India plays a significant role in shaping both the innovation and accessibility of these advancements. On one hand, patents promote innovation in biotechnology by stimulating investments in research and development (R&D).
On the other hand, the high prices associated with patented therapies and diagnostic tests create obstacles to access, particularly in lower and middle income countries like India, where the affordability of healthcare remains a significant issue. • Genetic Testing and Biomarker Patents: A considerable number of the diagnostics and treatments utilized in personalized medicine are covered by patents, including genetic tests for cancer risk (e. g. , BRCA1/BRCA2) and targeted therapies for certain genetic alterations (e. g. , EGFR mutations in lung cancer). The steep costs of these patented tests and treatments can restrict access to essential care, especially in India, where economic disparities hinder many individuals from affording cutting-edge therapies.
• Targeted Therapies and Cancer Treatments: India has witnessed notable progress in the availability of generic oncology medications, including targeted therapies. However, personalized treatments—such as those aimed at specific genetic changes—are often costly due to patent exclusivity, resulting in higher financial strain for patients in India. The Impact of Indian Patent Law on Personalized Medicine India's patent framework, regulated by the Patents Act of 1970, has seen noteworthy reforms to comply with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which India accepted as a member of the World Trade Organization (WTO). These changes have significantly influenced the advancement of personalized medicine, particularly regarding the need to balance innovation, public health, and access to cost effective treatments.
Section 3(d) of the Patents Act: Curbing "Evergreening" of Patents Section 3(d) of the Patents Act serves as a vital clause that affects the patenting of pharmaceutical products in India, especially concerning personalized medicine. This section was instituted to prevent evergreening, a practice where pharmaceutical companies make minor modifications to existing medications and re-patent them to prolong their exclusivity period. Evergreening has faced considerable criticism for restricting access to generic drugs and escalating the prices of medications. Section 3(d) explicitly states that new versions of known substances—whether in the form of salts, polymorphs, metabolites, or combinations—are not eligible for patents unless the new version demonstrates a notable improvement in therapeutic effectiveness compared to the known substance.
This provision aims to combat the trend of implementing minor adjustments to existing medications to prolong patent protection without providing any significant therapeutic advancement. Consequences for Personalized Medicine: Personalized medicine frequently entails tailoring treatments based on an individual’s genetic profile or other personal characteristics. This method may occasionally lead to the creation of minor variations of existing drugs that could offer improved efficacy or reduced side effects for particular patient groups. Nonetheless, Section 3(d) may restrict the patentability of these modifications if they do not show a significant increase in therapeutic advantages.
For example, a newly formulated cancer drug designed for a specific genetic variant might not qualify for a patent under this section if it does not demonstrate substantial enhancement over the previous version of the drug. This provision guarantees that only genuinely innovative medicines can be patented, thereby preventing the monopolization of drugs through incremental changes and promoting the availability of more affordable generic options. This is particularly pertinent in India, where medication costs are a significant concern and ensuring access to treatments is a public health priority. Case Example: The Novartis v. Union of India case (2013) exemplifies Section 3(d) in practice. Novartis aimed to secure patent protection for Glivec (Imatinib Mesylate), a leukemia treatment.
The Indian Supreme Court ruled against the patent, indicating that the minor alteration to Glivec did not fulfill the necessary standard of "significant enhancement in efficacy. " This ruling was celebrated as a triumph for public health, as it enabled the production and sale of generic versions of Glivec at considerably lower prices, making the medication accessible to countless patients.
Balancing Innovation and Public Health India's patent system seeks to strike a balance between encouraging innovation and meeting public health needs, making sure that essential treatments are accessible to the population at reasonable prices. Although the TRIPS agreement mandates that countries provide patents on pharmaceutical inventions, India has maintained considerable flexibilities within its patent legislation, such as Section 3(d) and the capacity to issue compulsory licenses. These flexibilities are instrumental in preventing patent monopolies from obstructing access to vital medications, particularly in critical fields like cancer therapy, where personalized medicines can greatly enhance patient outcomes but also present issues related to high treatment costs.
Challenges for Personalized Medicine: The creation and advancement of personalized therapies often encounter obstacles due to the strict patenting conditions outlined in Section 3(d). The requirement for substantial enhancements in efficacy can lead to delays or block the patenting of new versions of existing drugs tailored for particular patient groups or genetic profiles. Nevertheless, the capacity to issue compulsory licenses and produce generic medications alleviates these challenges, ensuring that personalized treatments remain attainable for the Indian populace at reasonable prices. Compulsory Licensing and the Affordability of Personalized Medicine in India Compulsory licensing is a mechanism under patent law that allows a government to authorize the production of a patented item or the use of a patented method without the patent holder's approval.
This provision is frequently used to tackle public health crises, guarantee access to essential medications, or lower costs for consumers, particularly in lower-income nations. In India, compulsory licensing has been a vital instrument in addressing the exorbitant prices of medicines and making sure that essential drugs are available to a wider segment of the population. As personalized medicine rapidly evolves, which customizes medical treatments based on patients' genetic, environmental, and lifestyle factors, India encounters the challenge of making this advanced healthcare technology affordable and accessible to its vast and diverse population.
The following points illustrate the relationship between compulsory licensing and the affordability of personalized medicine in India: The Costs of Personalized Medicine Personalized medicine typically requires advanced diagnostic tests, genetic evaluations, and specialized therapies, which can be expensive due to their highly specialized nature. These treatments usually come with high expenses for both the diagnostic technologies (e. g. , genomic sequencing) and the biologically engineered or targeted drugs utilized in therapy. Notable instances include treatments for cancer, rare genetic disorders, and other conditions that require individualized approaches based on a person’s genetic profile. In nations like India, where healthcare budgets are limited, the affordability of personalized medicine becomes a pressing issue.
The combination of significant initial costs for technology and the continual necessity for pricey medications can render these treatments out of reach for most of the population. India's Patent Law and Compulsory Licensing India's patent system, especially following the 2005 amendments to the Indian Patent Act, permits compulsory licensing under particular conditions. Section 84 of the Indian Patents Act empowers the government to grant a compulsory license for a patented invention if the patent owner does not fulfill certain requirements, such as: • The patented product being unavailable in the market at a reasonable price. • Inadequate supply of the product within the country. • The patent not being utilized (that is, the invention is not being produced or employed in India).
Moreover, India has committed to international agreements like the Trade-Related Aspects of Intellectual Property Rights (TRIPS), which contain clauses on compulsory licensing, particularly during public health emergencies. India notably exercised this right in 2012 when it issued a compulsory license for the cancer medication Nexavar (sorafenib), manufactured by Bayer. This decision was made due to high prices and lack of availability to Indian patients, leading the government to permit local generic manufacturing of the drug. Application of Compulsory Licensing on Personalized Medicine Customized medicine, particularly through biologics and advanced therapies, is frequently patented by large global pharmaceutical firms. These firms are able to establish high prices for these treatments because of their intellectual property rights.
The introduction of compulsory licensing could significantly contribute to making these therapies more affordable. Enhanced Access to Expensive Medications: With compulsory licensing, Indian companies could produce generic versions of costly personalized medicines and diagnostic tools, thus decreasing prices and making them more accessible to the Indian populace. Boosting Competition: Granting a compulsory license would enable multiple manufacturers to create generic versions of the patented products, leading to increased competition and further lowering prices. Emphasis on Public Health Requirements: Compulsory licensing could be activated in situations where there is an urgent demand for specific life-saving treatments, such as those used in personalized cancer care or genetic conditions.
This would allow India to tackle public health challenges without relying solely on market forces to adjust. Enhanced Domestic Manufacturing: By promoting local production, India could decrease its dependency on costly imports, resulting in a reduction of the overall expenses associated with personalized medicine. Policy Suggestions for Improving Access to Personalized Medicine To achieve a balance between fostering innovation and ensuring access to personalized medicine, India may explore a variety of policy strategies: Targeted Application of Compulsory Licensing: India could limit the use of compulsory licensing to the most essential treatments, particularly those that lack sufficient alternatives in the market. This method would guarantee that the tool is applied thoughtfully and only when necessary to meet public health demands.
Government-Funded Innovation and R&D: To support compulsory licensing, the Indian government might allocate resources toward domestic research and development of personalized medicine technologies. This investment would lessen dependence on foreign patents and stimulate local innovation. Encouraging Collaborations Between Multinational Corporations and Local Producers: Instead of turning to compulsory licensing, India could promote partnerships or voluntary licensing agreements between multinational pharmaceutical firms and local manufacturers. Such collaborations could help reduce costs while still honoring intellectual property rights.
Regulatory Framework and Quality Assurance: Any generic products created under compulsory licensing should adhere to stringent safety and efficacy standards. The Indian government could strengthen the regulatory system to ensure that generic personalized medicines undergo the same thorough evaluations as their branded versions. Tiered Pricing Models Tiered pricing, which adjusts drug prices according to a country's income level, could play a vital role in advancing personalized medicine. India has the opportunity to negotiate more affordable prices for personalized treatments, making them accessible to its citizens. • Example of HIV/AIDS Drugs: Initiatives like the Global Fund to Fight AIDS, Tuberculosis, and Malaria have enabled tiered pricing for antiretroviral (ARV) medications.
A comparable strategy could be applied to personalized cancer therapies, allowing lower-income patients in India to obtain these treatments at reduced costs. Scope and Limitation The research will concentrate on India, specifically examining how its intellectual property (IP) regulations influence access to personalized medicine. It particularly investigates the impact of patents and compulsory licensing on enhancing availability of personalized therapies for conditions such as cancer, genetic ailments, and infectious diseases. The study covers the period following the implementation of TRIPS, evaluating its effects on innovative treatment options. This research relies on secondary data sources, including legal documentation, scholarly articles, and case studies, and does not involve gathering primary data.
Consequently, it may be constrained by the reliability and availability of these sources. While the results are relevant to India, they might not be completely applicable to other nations, particularly those with distinct healthcare and patent frameworks. The swift advancement of personalized medicine and new technologies like gene editing could potentially exceed the scope of this research. Additionally, the intricate nature of IP laws and possible variations in their interpretation may limit the accuracy of the conclusions. Ethical considerations and socio-economic factors affecting access to medicine will be examined in general terms, but they fall outside the core focus of this study.
Suggestion To improve access to personalized medicine in India, the government could consider increasing the implementation of compulsory licensing to lower costs and broaden access to generic versions of patented treatments. Promoting public-private partnerships could facilitate the costeffective development and distribution of therapies. Furthermore, encouraging the production of biosimilars and generics through simplified regulatory processes could help reduce prices. Modifying intellectual property laws to prevent abuses, such as evergreening, would create a balance between innovation and public health requirements. Investing in healthcare infrastructure, particularly for genetic testing, is essential for ensuring widespread access. A National Strategy for Personalized Medicine could help synchronize efforts across various sectors to guarantee equitable distribution.
Raising public awareness about the advantages of personalized medicine and the significance of intellectual property laws is also important. Lastly, creating ethical guidelines for the utilization of genetic data will safeguard privacy and ensure fair access for everyone. Conclusion India’s intellectual property framework significantly influences the availability and costeffectiveness of personalized medicine. Although the Indian patent system offers essential protections for innovation, it also incorporates flexibilities—such as compulsory licensing and the utilization of generics—that can be utilized to enhance access to vital therapies. The nation's strong generic drug sector, coupled with tiered pricing and compulsory licensing, has effectively increased access to life-saving treatments, especially in the context of HIV/AIDS.
As personalized medicine advances, India must strategize on how to balance the necessity of safeguarding intellectual property with the critical need to guarantee fair access to these groundbreaking therapies. The implementation of compulsory licensing, the creation of generic biologics, and the use of TRIPS flexibilities will be essential in making sure that personalized medicine is not only a benefit for a select few but also serves as a means to enhance public health throughout the country.
Bibliography
https://www.healthcareradius.in/clinical/treatment/precision-medicine-addressing-indiashealth-challenge https://aishwaryasandeep.in/intellectual-property-rights-and-personalised-medicine/ https://vajiramandravi.com/quest-upsc-notes/compulsory-licensing/ https://www.personalizedmedicinecoalition.org/wpcontent/uploads/2024/01/strategic_plan.pdf https://www.clearias.com/evergreening-of-patent/